



July 11, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Outcome of Board Meeting held on July 11, 2026

Ref.: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

The Board of Directors of the Mankind Pharma Limited (“Company”) at its meeting held today i.e. July 11, 2026, has *inter-alia*, considered and approved the:

1. proposal for divestment of 100% stake held in Broadway Hospitality Services Private Limited (“Broadway”), a wholly owned subsidiary company; and
2. incorporation of a wholly owned subsidiary company in Netherlands (“WOS”) to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.

The detailed disclosure as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Circular”), for Items 1 and 2 is enclosed as Annexures I and II, respectively.

The meeting of Board of Directors of the Company commenced at 12:30 P.M. (IST) and concluded at 01:07 P.M. (IST).

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

**Annexure-I****Disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular:**

Sr. No.	Particulars	Information of such event												
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Details of Broadway as on March 31, 2026: <table border="1"> <thead> <tr> <th>Particulars</th> <th>Amount (₹ Crores)</th> <th>%ge contributed to Company's financials</th> </tr> </thead> <tbody> <tr> <td>Turnover/ Revenue</td> <td>9.63</td> <td>0.07</td> </tr> <tr> <td>Total Income</td> <td>9.90</td> <td>0.07</td> </tr> <tr> <td>Net worth</td> <td>38.99</td> <td>0.24</td> </tr> </tbody> </table>	Particulars	Amount (₹ Crores)	%ge contributed to Company's financials	Turnover/ Revenue	9.63	0.07	Total Income	9.90	0.07	Net worth	38.99	0.24
Particulars	Amount (₹ Crores)	%ge contributed to Company's financials												
Turnover/ Revenue	9.63	0.07												
Total Income	9.90	0.07												
Net worth	38.99	0.24												
2	Date on which the agreement for sale has been entered into	As part of the Company's strategy to divest it's non-core assets, the Board of Directors of the Company at its meeting held today i.e. July 11, 2026, has approved the divestment of 100% stake in Broadway, to AKRK Projects LLP and Partners and authorised for execution of Share Purchase Agreement.												
3	The expected date of completion of sale/disposal	Transaction is proposed to be completed within 90 days.												
4	Consideration received from such sale/disposal	Total consideration agreed is ₹ 49.00 Crores subject to closing adjustment, if any.												
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	<p>AKRK Projects LLP, having LLPIN: AAR-5397, a Limited Liability Partnership incorporated on January 8, 2020 having its Registered office situated at Unit No. 501, 5th Floor, Padma Tower II, 22, Rajendra Place, Central Delhi, New Delhi, Delhi, India, 110008 and its Partners ("Buyers").</p> <p>The Buyers do not belong to the Promoter or Promoter Group of the Company.</p>												
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Transaction would not fall within related party transactions.												
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Listing Regulations	Not applicable												
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable												

MANKIND PHARMA LIMITED

Annexure-II
Disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular:

Sr. No.	Particulars	Information of such event
1.	Name of the entity, date & country of incorporation, etc.	The Board of Directors of the Company at its meeting held today i.e. July 11, 2026 has approved the incorporation of a Wholly Owned Subsidiary (WOS) in Netherlands. Name: As would be approved by authorities in Netherlands Date of Incorporation: Not Applicable as proposed to be incorporated a new company. Country of Incorporation: Netherlands
2.	Name of holding company of the incorporated company and relation with the listed entity	The Company will be the holding company of the proposed WOS.
3.	Industry to which the entity being acquired belongs	Pharmaceutical Industry
4.	Brief background about the entity incorporated in terms of products / line of business	The new company would be operating in the capacity of holding investments in R&D assets and carrying out business development activities focused on treatment of niche therapies, either through joint venture or acquiring strategic interests, as the opportunities arises.
5.	Brief details of any governmental or regulatory approvals required for the incorporation	Incorporation of the proposed WOS will be under the applicable provisions of the Foreign Exchange Management Act & Regulations made thereunder, Reserve Bank of India Regulations/Guidelines & such other authorities in or outside India and subject to the necessary regulatory approvals/licences as may be required from the appropriate Authority(ies) in Netherlands.
6.	Nature of consideration - whether cash consideration or share swap and details of the same	The Company will contribute towards subscription of equity capital or other securities, as may be applicable, of the proposed WOS.
7.	Cost of subscription / price at which the shares are subscribed	Proposed Investment: Upto Euro 5 Million, in one or more tranches, to meet set-up, operating cost, procurement and further investments. The Company would be subscribing to Ordinary and / or other class of securities of proposed WOS, as per applicable regulatory provisions.
8.	Percentage of shareholding / control by the listed entity and / or number of shares allotted.	100% subscription to the share capital.

MANKIND PHARMA LIMITED